Next Article in Journal
Development and Challenges of Antimicrobial Peptides for Therapeutic Applications
Next Article in Special Issue
Inhibitory Activity of a Scorpion Defensin BmKDfsin3 against Hepatitis C Virus
Previous Article in Journal
The Effect of Different Antibiotic Regimens on Bacterial Resistance: A Systematic Review
Previous Article in Special Issue
More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin
Article

Designed Antimicrobial Peptides for Topical Treatment of Antibiotic Resistant Acne Vulgaris

1
Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, CA 94952, USA
2
Integrative Biosciences, College of Agriculture, Environment and Nutritional Sciences, Tuskegee University, Tuskegee, AL 36088, USA
*
Author to whom correspondence should be addressed.
Received: 26 December 2019 / Revised: 7 January 2020 / Accepted: 9 January 2020 / Published: 13 January 2020
(This article belongs to the Special Issue Antibacterial Peptides)
Acne vulgaris, caused by the Gram-positive bacterium Cutibacterium acnes, is a prevalent dermatologic condition with substantial cutaneous and psychological morbidity. Mild acne is treated with topical antibiotics with more severe inflammatory forms requiring the prolonged use of oral antibiotics, resulting in antimicrobial resistance development. Innovative treatment alternatives, providing complete microbicidal eradication with minimal safety issues and limited susceptibility to microbial resistance, are fervently sought. Designed antimicrobial peptides (dAMPs) are engineered analogs of naturally occurring AMPs that possess a reduced likelihood of developing bacterial resistance. Seven novel dAMP sequences were screened for in vitro bactericidal effectiveness against antibiotic resistant C. acnes clinical isolates. Five peptides (RP444, RP551, RP554, RP556, and RP557) exhibited potent in vitro antibacterial activity. The Therapeutic Index, a measure of specificity for killing multidrug resistant C. acnes over mammalian cells, was determined using bioluminescent human keratinocytes. The Therapeutic Index was highest for the disulfide dAMP, RP556, with a value of 130. The lead dAMP candidate RP556, was further evaluated in a multidrug-resistant C. acnes intradermal murine infection model. A topical application of 5 mg/mL RP556 (0.5%) eliminated infection. If these preclinical results are translated clinically, dAMPs may become a viable topical monotherapy for the treatment of recalcitrant acne infections. View Full-Text
Keywords: acne; antimicrobial peptides; bacterial resistance; multidrug resistance; topical treatment acne; antimicrobial peptides; bacterial resistance; multidrug resistance; topical treatment
Show Figures

Figure 1

MDPI and ACS Style

Woodburn, K.W.; Jaynes, J.; Clemens, L.E. Designed Antimicrobial Peptides for Topical Treatment of Antibiotic Resistant Acne Vulgaris. Antibiotics 2020, 9, 23. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics9010023

AMA Style

Woodburn KW, Jaynes J, Clemens LE. Designed Antimicrobial Peptides for Topical Treatment of Antibiotic Resistant Acne Vulgaris. Antibiotics. 2020; 9(1):23. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics9010023

Chicago/Turabian Style

Woodburn, Kathryn W., Jesse Jaynes, and L. E. Clemens 2020. "Designed Antimicrobial Peptides for Topical Treatment of Antibiotic Resistant Acne Vulgaris" Antibiotics 9, no. 1: 23. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics9010023

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop